Blood Glucose Test Strips Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Blood Glucose Test Strips Market is projected to expand from a valuation of USD 8.46 Billion in 2025 to USD 12.92 Billion by 2031, reflecting a CAGR of 7.31%. These diagnostic consumables, which utilize reagents to quantify sugar levels through glucometers, are seeing demand fueled by the intensifying global burden of diabetes and an aging population necessitating chronic care. Data from the International Diabetes Federation indicates that approximately 589 million adults were living with diabetes worldwide in 2024, a massive patient demographic that drives consumption as self-monitoring remains critical for maintaining glycemic control and averting complications within home healthcare environments.

However, the market faces a substantial obstacle in the form of growing consumer preference for Continuous Glucose Monitoring systems, which remove the necessity for frequent and painful finger-prick tests. This technological shift poses a risk to traditional strip sales volumes as patients increasingly adopt sensor-based devices that provide real-time metrics. Consequently, the rapid widespread adoption of these sophisticated alternatives has the potential to hinder the revenue growth of conventional testing supplies, even as the overall prevalence of diabetes continues to rise.

Market Drivers

The primary catalyst propelling market growth is the escalating global prevalence of diabetes mellitus, which necessitates accessible and frequent glucose monitoring solutions for effective condition management. As urbanization and lifestyle shifts drive the incidence of Type 2 diabetes, the expanding patient pool creates a proportional rise in the diagnostic testing volume needed to sustain glycemic control. A significant driver of this expansion is the identification of previously undiagnosed cases, which immediately transforms individuals into active consumers of testing supplies; according to the 'IDF Diabetes Atlas 11th Edition' released by the International Diabetes Federation in April 2025, nearly 252 million adults globally are currently living with undiagnosed diabetes, representing a vast latent market segment as screening initiatives ramp up.

Concurrently, the increasing adoption of home-based self-monitoring is redefining patient engagement and upholding demand for diagnostic consumables. This pivot toward preventive healthcare empowers patients to actively track blood sugar levels outside of clinical environments, thereby lowering the risks of acute complications and long-term hospitalizations, a trend supported by the proliferation of user-friendly testing devices that encourage regular checks and recurring strip purchases. The market’s robustness is reflected in the financial results of major industry players; for instance, Roche’s 'Annual Report 2024', published in January 2025, noted an 8% sales increase in its Diagnostics Division’s base business, while the International Diabetes Federation estimated in 2025 that diabetes accounted for USD 1.015 trillion in global health expenditure, underscoring the critical need for cost-effective management tools.

Market Challenges

The rapid expansion of Continuous Glucose Monitoring (CGM) systems presents a significant barrier to the growth of the traditional blood glucose test strips sector. In contrast to standard glucometers that demand a specific strip for each reading, CGM devices employ subcutaneous sensors to offer real-time, 24-hour glucose tracking, fundamentally shifting the diagnostic supply consumption model. As patients utilizing sensors reduce their reliance on frequent finger-prick testing - using strips primarily for backup or occasional calibration - the recurring sales volume that serves as the main revenue source for legacy manufacturers faces a direct and irreversible downturn.

Recent adoption metrics substantiate this displacement of conventional testing methods. Data from the American Diabetes Association indicates that in 2024, the utilization of continuous glucose monitoring technology rose to approximately 47% among youth and 37% among adults with type 1 diabetes in the United States. This significant migration toward sensor-based solutions suggests that a substantial fraction of the most intensive glucose monitoring users are departing the daily test strip market. Consequently, the widespread uptake of these advanced devices constrains the total addressable market for strips, effectively neutralizing potential revenue benefits that would otherwise stem from the rising global prevalence of diabetes.

Market Trends

The emergence of value-based bundled diabetes management services is fundamentally reshaping revenue mechanisms, transitioning the industry from transactional consumable sales to holistic subscription models. Manufacturers are increasingly incorporating test strips into comprehensive packages that feature remote coaching and data analytics, thereby securing long-term recurring revenue streams that are less vulnerable to price erosion. This approach improves patient adherence by emphasizing continuous care engagement over isolated testing, a model whose success is highlighted by DarioHealth’s 'Fourth Quarter and Full Year 2024 Financial and Operating Results' from March 2025, which reported a 398% year-over-year surge in recurring revenues from its B2B2C business channel to USD 5.6 million.

Simultaneously, the proliferation of private label and store-brand test strips is securing significant market share as payers and consumers prioritize cost containment. With healthcare systems facing the heavy economic weight of diabetes, there is an accelerated migration toward high-quality, lower-cost generic alternatives that are displacing legacy premium brands in retail environments. This trend fuels volume growth for manufacturers focused on white-label production who deliver affordability without sacrificing accuracy, a performance reflected in Sinocare Inc.’s '2024 Annual Report' from April 2025; the company, a key producer of cost-effective biosensing technologies, announced a net income of CNY 326.29 million, representing a 14.73% increase over the previous year.

Key Players Profiled in the Blood Glucose Test Strips Market

• Abbott Laboratories, Inc.
• Dexcom, Inc.
• F. Hoffmann-La Roche AG
• Medtronic PLC
• Ascensia Diabetes Care Holdings AG
• Sinocare Inc.
• Nemaura Medical Inc.
• Nipro Corporation
• ARKRAY, Inc.
• Senseonics Holdings, Inc.
• B. Braun Medical Inc.
• LifeScan Inc.
• Prodigy Diabetes Care LLC

Report Scope

In this report, the Global Blood Glucose Test Strips Market has been segmented into the following categories:

Blood Glucose Test Strips Market, by Type:

• Thick Film Electrochemical Films
• Thin Film Electrochemical Films
• Optical Strips

Blood Glucose Test Strips Market, by End-User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Blood Glucose Test Strips Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Glucose Test Strips Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.